Alnylam Pharmaceuticals, Inc. (FRA:DUL)

Market Cap	37.59B +19.5%
Revenue (ttm)	2.74B +53.2%
Net Income	37.13M
EPS	0.28
Shares Out	n/a
PE Ratio	1,012.44
Forward PE	34.02
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	20
Open	302.10
Previous Close	303.50
Day's Range	299.60 - 304.80
52-Week Range	198.70 - 423.00
Beta	n/a
RSI	26.29
Earnings Date	Feb 12, 2026

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clin...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2002
• Employees: 2,230
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: DUL

Financial Performance

In 2024, Alnylam Pharmaceuticals's revenue was $2.25 billion, an increase of 22.97% compared to the previous year's $1.83 billion. Losses were -$278.16 million, -36.82% less than in 2023.

Financial numbers in USD